论文部分内容阅读
目的观察参芪扶正注射液联合EP方案治疗晚期非小细胞肺癌的疗效和毒副作用。方法治疗组35例,对照组35例,均采用相同的EP化疗方案,足叶乙甙(VP-16)120mg/m2静脉滴注,第1～3d,顺铂(PDD)60mg静脉滴注,第1d,每21d为1个周期。3个周期为1个疗程。治疗组化疗期间常规静脉滴注参芪扶正注射液250ml,每日1次,连用14d为1个周期。3个周期为1个疗程。观察两组近期疗效,化疗后生活质量评价、血液毒性反应及免疫功能变化情况。结果参芪扶正注射液配合化疗组总有效率(45.7%)较单纯化疗组(42.9%)高,但差异无统计学意义(P>0.05),在改善患者生活质量、减轻化疗毒性方面明显优于单纯化疗组,差异有统计学意义(P<0.05)。治疗组其细胞免疫功能有不同程度提高,而对照组免疫能力下降,差异有统计学意义(P<0.05)。结论参芪扶正注射液联合EP方案治疗晚期非小细胞肺癌可降低化疗对患者的毒副反应,提高机体免疫功能,改善患者的生活质量。
Objective To observe the curative effect and side effects of Shenqi Fuzheng injection combined with EP regimen in the treatment of advanced non-small cell lung cancer. Methods 35 patients in the treatment group and 35 in the control group were treated with the same EP chemotherapy, intravenous infusion of VP-16 120mg / m2, intravenous drip of 1 ~ 3d and PDD 60mg, 1d, every 21d for a period. 3 cycles for a course of treatment. During the chemotherapy in the treatment group conventional intravenous infusion of Shenqi Fuzheng 250ml, 1 day, once every 14d for a cycle. 3 cycles for a course of treatment. The two groups were observed the short-term efficacy, quality of life after chemotherapy evaluation, hematological toxicity and changes in immune function. Results The total effective rate (45.7%) of Shenqi Fuzheng injection combined with chemotherapy group was higher than that of chemotherapy alone group (42.9%), but the difference was not statistically significant (P> 0.05). It was obviously superior in improving quality of life and reducing chemotherapy toxicity In simple chemotherapy group, the difference was statistically significant (P <0.05). The immune function of the treatment group increased to some extent, while the immunity of the control group decreased, the difference was statistically significant (P <0.05). Conclusion Shenqi Fuzheng injection combined with EP regimen in the treatment of advanced non-small cell lung cancer can reduce chemotherapy side effects on patients, improve immune function, and improve the quality of life of patients.